002223 鱼跃医疗
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入6,027,852-9.53%7,971,7347,101,6796,894,3086,725,687
减:营业总成本4,578,932-3.69%5,804,4265,605,8725,382,0584,887,664
    其中:营业成本3,005,842-6.85%3,866,8703,683,6433,565,2993,182,544
               财务费用(131,386)59.76%(157,469)(96,253)(8,638)127,900
               资产减值损失(6,424)-83.44%(92,980)(104,090)(20,634)(35,977)
公允价值变动收益----(4,106)2,1602,165(322)
投资收益21,502-83.54%143,208129,132115,831127,096
    其中:对联营企业和合营企业的投资收益----11,82313,2197,80611,535
营业利润1,753,251-32.83%2,893,4941,841,8041,688,0472,009,669
利润总额1,755,145-31.69%2,848,8351,842,4181,701,8442,018,647
减:所得税费用221,715-43.51%472,362269,728217,820262,037
净利润1,533,430-29.56%2,376,4721,572,6901,484,0241,756,610
减:非控股权益1,836-113.25%(19,381)(22,348)1,602(2,452)
股东净利润1,531,594-30.09%2,395,8531,595,0371,482,4221,759,062

市场价值指针
每股收益 (元) *1.537-30.29%2.4101.6101.4901.750
每股派息 (元) *0.400--0.8000.6000.3000.300
每股净资产 (元) *12.5038.56%11.7359.8368.2527.419
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容